The Clinical Use of Tipranavir in HIV Infection

23 Mar

Tipranavir in HIV Infection


Highly active antiretroviral therapy (HAART) has augmented the treatment and outcome of human immunodeficiency virus (HIV-1) infection. The inclusion of protease inhibitors (PIs) with a HAART regimen has been responsible for dramatic reductions in morbidity and mortality in cases of advanced infection. It is estimated that nearly 40 million people worldwide are infected with HIV. Suppression of HIV-1 replication is the goal of HAART. Lack of success in achieving this target usually leads to drug-resistant variants and subsequent virological rebound.

Resistance is a principal reason for the failure of HAART. Studies are demonstrating that new infections are resulting from transmission of resistant HIV-1 strains. For HAART to work successfully, the medications must be able to recognize the virus in the blood. Sometimes, however, the virus makes copies of itself that differ from the original. This change is called a mutation. The new copies are resistant to the current regimen, and this can lead to “virological failure.” Virological failure occurs when HAART fails to reach a viral load of non-detectable status. The degree of resistance can vary; in fact, resistance usually develops gradually over time.

On June 22, 2005, the U.S. Food and Drug Administration (FDA) approved tipranavir capsules (Aptivus, Boehringer Ingelheim) for the combination antiretro-viral treatment of HIV-1 infected adults. The FDA approved TPV for patients who are extremely treatment-experienced or who have HIV strains that are resistant to multiple PIs. Viagra Online Canadian Pharmacy

Tipranavir (TPV) is the first non-peptidic protease inhibitor (NPPI) developed for the treatment of HIV-1 infec-tion. Because of its unique and potent action against virus resistance to multiple PIs, TPV serves as a relevant option in the treatment-experienced population.